Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients

Acta Oto-Laryngologica

Volumn 129, Issue 11, 2009, Pages 1294-1299

  Grau, Juan José ^a   Caballero, Miguel ^b   Verger, Eugenia ^c   Monzó, Mariano ^b   Blanch, Jose Luís ^b  

^a ICMHO (Institut Clinic de Malalties Hemato Oncologiques)   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Advanced tumors; Chemotherapy; Head and neck cancer; Squamous cell carcinoma

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; PLATINUM DERIVATIVE; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; DESQUAMATION; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; FLUID RETENTION; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PALLIATIVE THERAPY; PARESTHESIA; PATIENT COMPLIANCE; PHARYNGITIS; PLATELET TOXICITY; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOPHLEBITIS; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OTORHINOLARYNGOLOGIC NEOPLASMS; PACLITAXEL; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 70350049238     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016480802590451     Document Type: Article

References (18)

1. León X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to platinum-based chemotherapy. J Clin Oncol 2005;/17:/418-24.
2. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005;/16:/1243-52.
3. Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005;/14:/ 466-479
4. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;/ 24:/1759-63.
5. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 2000;/83:/775-81.
6. Teknos TN, Cox C, Yoo S, Chepeha DB,Wolf GT, Bradford CR, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002;/24:/1004-11.
7. Lentsch EJ, Goudy S, Sosnowski J, Major S, Bumpous JM. Microvessel density in head and neck squamous cell carcinoma primary tumors and its correlation with clinical staging parameters. Laryngoscope 2006;/116:/397-400.
8. Lau D, Guo L, Gandara D, Young LJ, Xue L. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs 2004;/15:/871-5.
9. Moosmann P, Egli F, Stahel RA, Jost L. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 2003;/26:/568-72.
10. Brotherton TW, Ritch P, Ervin T. Phase II multicenter trial of paclitaxel weekly one hour infusion in previously treated advanced head/neck cancer. Proc ASCO 2001;20:231 (abstract).
11. Therasse P, Arbuck SG, Eisenhauer AE, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;/92:/205-16.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;/53:/457-81.
13. Hitt R, Irigoyen A, Nuñ ez J, Grau J, Garcia-Saenz J, Pastor M, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN). Spanish Head and Neck Cancer Group (TTCC). Proc ASCO 2007;25:302s (abstract).
14. Hitt R, Amador ML, Quintela-Fandino M, Jimeno A, del Val O, Hernando S, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 2006;/106:/106-11.
15. Gately S, Kamen BA. The antiangiogenic scheduling of lower dose cancer chemotheraphy. Cancer J 2001;/7:/ 427-436
16. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;/14:/ 13-19
17. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;/62:/6938-43.
18. Forastiere AA, Neuberg D, Taylor SG 4th, DeConti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. Cancer 1998;/82:/2270-4.